Paolini, Biagio

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit

Triulzi, T., Regondi, V., De Cecco, L., Cappelletti, M. R., Di Modica, M., Paolini, B., Lollini, P. L., Di Cosimo, S., Sfondrini, L., Generali, D., et al. (2018) · British Journal of Cancer

HER2/EGFR in Cancer ResearchCancer Immunotherapy and Biomarkers

Cited by 94

An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).

Necchi, A., Magazzu, D., Anichini, A., Raggi, D., Giannatempo, P., Nicolai, N., Colecchia, M., Paolini, B., Coradeschi, E., Tassi, E., et al. (2016) · Journal of Clinical Oncology

Testicular diseases and treatmentsLymphoma Diagnosis and Treatment

Cited by 17